Tonix Pharmaceuticals Holding Corp.
TNXPTonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, immunology, and infectious diseases. The company specializes in using its proprietary technology platforms to develop novel therapies for conditions such as neurological disorders, grief, fibromyalgia, and COVID-19.
Company News
Tonix Pharmaceuticals announced a second commercial payer agreement with a leading GPO effective June 1, 2026, providing coverage for TONMYA® to approximately 17 million additional U.S. commercial lives. Combined with the first agreement announced in May 2026, TONMYA now has commercial coverage for approximately 52 million U.S. lives (29% of tot...
Bay Area Lyme Foundation raised $900,000 at its annual LymeAid 2026 gala, featuring entertainment by Dana Carvey and Chris Isaak. The foundation presented its inaugural Neil L. Spector, MD, Legacy Award to Timothy Haystead, PhD, and distributed $300,000 in Emerging Leader Awards to researchers studying Lyme disease diagnostics and tick-borne infe...
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 featuring a retrospective U.S. real-world claims analysis of fibromyalgia patients using data from April 2021-April 2024. TONMYA (cyclobenzaprine HCl sublingual tablets), approved by the FDA on August 15, 2025, and commercially launched on November 17, 2025, is the first new pres...
Tonix Pharmaceuticals announced the publication of pharmacokinetic data for TONMYA (cyclobenzaprine HCl sublingual tablets) in the peer-reviewed journal Clinical Pharmacology in Drug Development. The study demonstrated that TONMYA, the first new FDA-approved fibromyalgia treatment in over 15 years (approved August 2025, commercially launched Nove...
Tonix Pharmaceuticals announced that CEO Seth Lederman will deliver a company presentation at BIO-Europe Spring 2026 in Lisbon on March 24, 2026. The presentation will highlight the company's commercial-stage biotechnology portfolio focused on CNS and immunology treatments, including TONMYA® for fibromyalgia (launched November 2025 with over 1,5...
